No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Spyre Therapeutics Analyst Ratings
Express News | Spyre Therapeutics Inc : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $45
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, Its Novel Half-life Extended IL-23 Antibody
Wolfe Research Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $27
Strategic Potential of Spyre Therapeutics in Combination Therapies for Inflammatory Diseases
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Hold Rating